Intra-articular Injections of Platelet-rich Plasma, Hyaluronic Acid, or Corticosteroids for Knee Osteoarthritis
NCT ID: NCT04980105
Last Updated: 2021-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
150 participants
INTERVENTIONAL
2020-03-02
2021-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intra-Articular, Single-shot Injection of Hyaluronic Acid and Corticosteroids in Knee Osteoarthritis
NCT03047096
Comparison of Efficacy of Intra-articular Morphine vs Methylprednisolone in Patients With Knee Osteoarthritis.
NCT06163755
Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial
NCT02995083
Knee Osteoarthritis: Platelet Rich Plasma or Hyaluronic Acid
NCT03801564
Efficacy of Hyaluronic Acid and Platelet-rich Plasma Combination in Knee Osteoarthritis
NCT03211650
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Platelet-rich plasma arm
Platelet-rich plasma
Two intra-articular injections of autologous platelets-rich plasma (PRP) in two weeks intervals between the first and the second injection.
Hyaluronic acid arm
Hyaluronic acid
Two intraarticular injections of hyaluronic acid (60 mg) in two weeks intervals between the first and the second injection
Methylprednisolone acetate arm
Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)
Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Platelet-rich plasma
Two intra-articular injections of autologous platelets-rich plasma (PRP) in two weeks intervals between the first and the second injection.
Hyaluronic acid
Two intraarticular injections of hyaluronic acid (60 mg) in two weeks intervals between the first and the second injection
Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)
Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with knee pain that had been continuing for at least 12 months with no relief using anti-inflammatory medications and that deteriorated with weight-bearing
* Knee osteoarthritis that classified as mild-moderate or moderate-severe (Kellgren-Lawrence Grade 2, 3, or 4)
Exclusion Criteria
* The recent history of knee trauma
* Autoimmune rheumatic diseases
* Accompanying severe hip OA
* Thrombocytopenia or other blood diseases
* Immunosuppressive or anticoagulant treatment
* The invasive procedure applied to the knee
* Intra-articular steroid injection to the knee within the previous 12 months
* Previous joint infection
* Uncontrolled systemic diseases such as diabetes or hypertension, and cancer
* Excessive varus/valgus knee deformity
35 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Wasit
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Usama Al-Sari
Senior Lecturer of Rheumatology M.B.,Ch.B, MSc , PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Usama A Al-Sari, PhD
Role: PRINCIPAL_INVESTIGATOR
UOW
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Wasit
Wāsiţ, , Iraq
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UOW/MS102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.